Top of the page
Alpha-1 antitrypsin (AAT) is a protein normally found in the lungs and the bloodstream. It helps protect the lungs from the damage caused by inflammation that can lead to emphysema and chronic obstructive pulmonary disease (COPD). People whose bodies do not produce enough of this protein (AAT deficiency) are more likely to develop emphysema and do so at a younger-than-normal age (30 to 40 years old). AAT deficiency is a rare disorder and is the only known genetic (inherited) factor that increases your risk of developing COPD.
Your doctor may suspect you have an AAT deficiency if you:footnote 3
An AAT deficiency test measures the level of AAT in the blood. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 clinical guidelines recommend a one-time testing for all people with COPD.footnote 1 And the Canadian Thoracic Society suggests testing for an AAT deficiency in people diagnosed with COPD who:footnote 2
It is extremely important that you do not smoke if you have an AAT deficiency. Smokers with this condition may suffer devastating disease at a young age. People with this condition who have never smoked usually do not have significant symptoms at any age.
Treatment for COPD may include inhaled medicines to help you breathe easier. It may also include participating in a pulmonary rehabilitation program to learn exercise, breathing tips and other ways to help yourself stay as healthy and strong as you can. In addition, your doctor may suggest that you are eligible for alpha-1 antitrypsin protein replacement. To be considered for this treatment, the following are basic guidelines:
Infusions of replacement alpha-1 antitrypsin are given weekly. Talk with your doctor about benefits of the therapy, and if you are eligible for this therapy.
Citations Global Initiative for Chronic Obstructive Lung Disease (2017). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd. Accessed November 27, 2016.Marciniuk, DD et al. (2012). Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. Canadian Respiratory Journal, 19(2): 109–116. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373286. Accessed February 12, 2018. [Erratum in Canadian Respiratory Journal, 19(4): 272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411393. Accessed February 12, 2018.]American Thoracic Society/European Respiratory Society (2003). ATS/ERS: Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine, 168(7): 820–822.
Adaptation Date: 8/18/2021
Adapted By: Alberta Health Services
Adaptation Reviewed By: Alberta Health Services
To learn more about Healthwise, visit Healthwise.org.
© 1995-2021 Healthwise, Incorporated. All rights reserved. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.